ArticleBMC pharmacology & toxicology2025
Therapeutic potential of zinc oxide/berberine nanoparticles in mitigating acute respiratory distress syndrome: in vivo and in silico approaches.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation and oxidative stress strongly contribute to the pathophysiology of acute respiratory distress syndrome (ARDS), which is a life-threatening pulmonary disease. Zinc oxide/berberine nanoparticles (ZnO/Ber-NPs) have been shown to have a protective effect against COVID-19 because of their antioxidant, anti-inflammatory, and antiviral properties. Hence, this study aimed to investigate the therapeutic action of ZnO/Ber NPs against ARDS. ARDS was induced by a combination of lipopolysaccharides and nicotine (LPS + Nt).
methodsMale mice were induced with LPS + Nt alternately for 14 days and then orally administered berberine (Ber) (1.24 mg/kg), ZnO NPs (2.06 mg/kg), a ZnO NP + Ber mixture (3.3 mg/kg), or ZnO/Ber NPs (3.3 mg/kg). Assessment of (1) prooxidant and antioxidant (enzymatic and nonenzymatic) parameters, (2) inflammatory and anti-inflammatory markers (TNF-α, IL-1β, IFN-ɣ, NF-kB and IL-10), (3) lung lesion parameters, triggering receptor expressed on myeloid cells-1 (TREM-1), myeloperoxidase enzyme (MPO) and angiotensin-converting enzyme-2 (ACE II), (4) and apoptotic markers (Bax and p53) were performed via standardized methods. In addition, ZnO, Ber, and ZnO/Ber NPs were examined for their bioactivities against the following proteins GPx, code: 2R37, SOD protein, code: 1PL4, ACE2 protein, code: 6M1D, TREM1 protein, code: 1Q8M and MPO protein, code: 6WYZ.
resultsThe results demonstrated that LPS + Nt administration significantly elevated oxidative stress, proinflammatory, lung lesion, and proapoptotic parameters while reducing antioxidant and ACE II levels in the lung. Treatments, especially ZnO/Ber NPs, significantly attenuated the oxidative stress and inflammation associated with ARDS, as indicated by the restoration of antioxidant enzyme activities, decreased lipid peroxidation, and proinflammatory TNF-α and IFN-ɣ levels. ZnO/Ber NPs significantly decreased TREM-1 and MPO in association with elevated ACE II. In addition, ZnO/Ber NPs decreased the expression of apoptotic markers and decreased the number of alveolar inflammatory infiltrates to the minimal score. Molecular docking analysis revealed that ZnO/Ber NPs showed the strongest binding with all tested receptors.
conclusionZnO/Ber NPs exhibit antioxidant, anti-apoptotic, and anti-inflammatory effects and act as therapeutic candidates against ARDS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.